Evidence map›Paper›PMID 33886059›Full record

ReviewMolecular and cellular biochemistry2021

A review of possible therapies for multiple sclerosis.

Hui Li, Gaojian Lian, Guang Wang, Qianmei Yin, Zehong Su

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular and cellular biochemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hui LiHengyang Medical School, University of South China, Hengyang City, 421001, Hunan Province, China.
Gaojian LianHengyang Medical School, University of South China, Hengyang City, 421001, Hunan Province, China.
Guang WangHengyang Medical School, University of South China, Hengyang City, 421001, Hunan Province, China.
Qianmei YinHengyang Medical School, University of South China, Hengyang City, 421001, Hunan Province, China.
Zehong SuHengyang Medical School, University of South China, Hengyang City, 421001, Hunan Province, China. zehongsu@qq.com.ORCID http://orcid.org/0000-0001-6448-4188

Funding

Key Laboratory of Ecological Environment and Critical Human Diseases Prevention of Hunan Province Department of Education 20K107Natural Science Foundation of Hunan Province Grant 2019JJ40243
6 · The paper itself

Abstract

Multiple sclerosis (MS) is an autoimmune chronic inflammatory disease of the central nervous system with a wide range of symptoms, like executive function defect, cognitive dysfunction, blurred vision, decreased sensation, spasticity, fatigue, and other symptoms. This neurological disease is characterized by the destruction of the blood-brain barrier, loss of myelin, and damage to neurons. It is the result of immune cells crossing the blood-brain barrier into the central nervous system and attacking self-antigens. Heretofore, many treatments proved that they can retard the progression of the disease even though there is no cure. Therefore, treatments aimed at improving patients' quality of life and reducing adverse drug reactions and costs are essential. In this review, the treatment approaches to alleviate the progress of MS include the following: pharmacotherapy, antibody therapy, cell therapy, gene therapy, and surgery. The current treatment methods of MS are described in terms of the prevention of myelin shedding, the promotion of myelin regeneration, and the protection of neurons.

Indexed as

Combined Modality TherapyHumansMultiple SclerosisPrognosisCell therapyDisease-modifying treatmentGene therapyMultiple sclerosisSymptomatic therapy

Identifiers

PMID33886059

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.